The Danaher Corporation (DHR) is gaining attention for various reasons. Wall Street analysts are repeatedly bullish on the stock, signaling strong future performance. Passionate investors bought shares increasing their holdings, such as Root Financial Partners LLC and David Wealth Management LLC buying 1,494 and 30,191 shares respectively. However, other institutions are reportedly selling their stock, for instance, Compagnie Lombard Odier SCmA sold over 3,000 shares indicating mixed sentiment. Concerns were raised over insiders selling US$15m in stock. Jim Cramer expressed disappointment in Danaher for an unnamed reason despite a later admission of tremendous respect for the company. Claims of Danaher hitting a new 1-year low were twice reported. Reasons for the bearish aspect are few, but DHR is still being touted as the best medical device stock to buy and among the best for long-term low-risk stock. The corporation has released reports of steady financial performance in 2024 and reassures strategic growth amidst market challenges. Regardless, Danaher was seen having missed the EPS by 5.5%. Investors are encouraged to pay close attention to the company's strategic moves and upcoming financial updates.
Danaher Corporation DHR News Analytics from Tue, 03 Sep 2024 07:00:00 GMT to Sat, 15 Feb 2025 13:47:31 GMT - Rating 5 - Innovation 5 - Information -3 - Rumor 0
